Nicox SA announced the publication of preclinical IOP-lowering results on a new class of non-prostaglandin analog (PGA), nitric oxide (NO)-donating compounds, in the Journal of Ocular Pharmacology and Therapeutics.1 The NO-mediated IOP-lowering effect in this new class of compounds is enhanced by concomitant action of phosphodiesterase type-5 (PDE5) inhibition within the same molecule.
“This new class of compounds, in which we optimized and enhanced the activity of nitric oxide, has been developed using the years of expertise and research in this area within Nicox,” Michele Garufi, Chairman and CEO of Nicox, said in a company news release. “We have shown with Vyzulta and our promising phase 3 product candidate, NCX 470, that nitric oxide can bring additional efficacy on top of a prostaglandin analog. This new class of compounds enhance the nitric oxide-mediated intraocular pressure lowering effect with the concomitant action of phosphodiesterase type-5 inhibition. We identified product candidates in this class which could potentially be used as monotherapy, or in combination with prostaglandin analogs or other intraocular pressure lowering agents, to add efficacy to existing therapies.”
The published data on NCX 1741, an analog of Nicox’s development candidate NCX 1728, compared its IOP lowering effect to that of travoprost in a non-human primate model of ocular hypertension. This publication reports that NCX 1741 reduced IOP to a similar extent to travoprost, with faster onset of activity. Travoprost is a prostaglandin analog, a class of molecules which are considered standard of care for IOP lowering in humans.
NCX 1728 is the first in this new class of compounds to be selected for development. Nicox will conduct a full characterization of the ophthalmic formulations of NCX 1728 prior to initiating non-clinical testing required for filing an IND application. Nicox owns all exclusive worldwide rights to NCX 1728 and NCX 1741.
The publication can be found at https://pubmed.ncbi.nlm.nih.gov/33595367/.
1 Bastia et al, Journal of Ocular Pharmacology and Therapeutics, 2021. doi: 10.1089/jop.2020.0126. Epub ahead of print. PMID: 33595367.